D-133 Solution
NDC Package 58264-0139-1
Package Information
D-133 (calcium fluoride, silicon dioxide, tribasic calcium phosphate, calcium sulfate anhydrous, ferrosoferric phosphate, potassium chloride, dibasic potassium phosphate, potassium sulfate, magnesium phosphate, dibasic trihydrate, sodium phosphate, dibasic, heptahydrate, sodium chloride, and sodium sulfate) solution is a medication used as Mineral imbalances. This formulation utilizes a solution delivery system. Marketed by Dna Labs, Inc., this product is identified by NDC 58264-0139.
Identification & Billing
Clinical Specifications
- CALCIUM FLUORIDE 8 [hp_X]/mL
- CALCIUM SULFATE ANHYDROUS 6 [hp_X]/mL
- DIBASIC POTASSIUM PHOSPHATE 6 [hp_X]/mL
- FERROSOFERRIC PHOSPHATE 6 [hp_X]/mL
- MAGNESIUM PHOSPHATE, DIBASIC TRIHYDRATE 6 [hp_X]/mL
- POTASSIUM CHLORIDE 6 [hp_X]/mL
- POTASSIUM SULFATE 6 [hp_X]/mL
- SILICON DIOXIDE 8 [hp_X]/mL
- SODIUM CHLORIDE 6 [hp_X]/mL
- SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE 6 [hp_X]/mL
- SODIUM SULFATE 6 [hp_X]/mL
- TRIBASIC CALCIUM PHOSPHATE 6 [hp_X]/mL
- Blood Coagulation Factor - [EPC] (Established Pharmacologic Class)
- Calcium - [CS]
- Calculi Dissolution Agent - [EPC] (Established Pharmacologic Class)
- Cations, Divalent - [CS]
- Increased Coagulation Factor Activity - [PE] (Physiologic Effect)
- Increased Large Intestinal Motility - [PE] (Physiologic Effect)
- Inhibition Large Intestine Fluid/Electrolyte Absorption - [PE] (Physiologic Effect)
- Inhibition Small Intestine Fluid/Electrolyte Absorption - [PE] (Physiologic Effect)
- Magnesium Ion Exchange Activity - [MoA] (Mechanism of Action)
- Osmotic Activity - [MoA] (Mechanism of Action)
- Osmotic Laxative - [EPC] (Established Pharmacologic Class)
- Phosphate Binder - [EPC] (Established Pharmacologic Class)
- Phosphate Chelating Activity - [MoA] (Mechanism of Action)
- Potassium Compounds - [CS]
- Potassium Salt - [EPC] (Established Pharmacologic Class)
- Stimulation Large Intestine Fluid/Electrolyte Secretion - [PE] (Physiologic Effect)
Regulatory & Marketing
Hierarchy Structure
- 58264 - Dna Labs, Inc.
- 58264-0139 - D-133
- 58264-0139-1 - 29.57 mL in 1 BOTTLE, GLASS
- 58264-0139 - D-133
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 58264-0139-1 identifies a specific commercial package of 29.57 ml in 1 bottle, glass of D-133, a human over the counter drug labeled by Dna Labs, Inc.. This solution is formulated for sublingual use and contains calcium fluoride; calcium sulfate anhydrous; dibasic potassium phosphate; ferrosoferric phosphate; magnesium phosphate, dibasic trihydrate; potassium chloride; potassium sulfate; silicon dioxide; sodium chloride; sodium phosphate, dibasic, heptahydrate; sodium sulfate; tribasic calcium phosphate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Dna Labs, Inc. on January 01, 1990. The current certification is valid through December 31, 2026.
How is this Dna Labs, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 58264013901. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.